Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Aminopyridines
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Breast Neoplasms
/ drug therapy
Chemical and Drug Induced Liver Injury
/ enzymology
Female
Humans
Letrozole
/ administration & dosage
Liver
/ drug effects
Middle Aged
Piperazines
/ administration & dosage
Protein Kinase Inhibitors
/ adverse effects
Purines
/ administration & dosage
Pyridines
/ administration & dosage
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Zoledronic Acid
/ administration & dosage
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
15
10
2019
medline:
21
10
2020
entrez:
15
10
2019
Statut:
ppublish
Résumé
CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.
Identifiants
pubmed: 31609762
doi: 10.1097/CAD.0000000000000845
pii: 00001813-202001000-00013
doi:
Substances chimiques
Aminopyridines
0
Piperazines
0
Protein Kinase Inhibitors
0
Purines
0
Pyridines
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Zoledronic Acid
6XC1PAD3KF
Letrozole
7LKK855W8I
palbociclib
G9ZF61LE7G
ribociclib
TK8ERE8P56
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-89Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2018; 68:394–424
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med. 2010; 134:e48–e72
Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American Joint Committee on Cancer Breast Cancer Staging System Oncologist. 2017; 22:1292–1300
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer N Engl J Med. 2016; 375:1925–1936
Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Medi. 2016; 375:1738–1748
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol. 2017; 35:3638–3646
El Rassy E, Bakouny Z, Assi T, Kattan J. Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference? Future Oncol. 2018; 14:891–895
Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib Breast Cancer Res Treat. 2017; 166:41–54
Petrelli F, Ghidini A, Pedersini R, Cabiddu M, Borgonovo K, Parati MC, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat. 2019; 174:597–604
Das P, Ali A, Simmonds K, Mckenna L. Effects of sunitinib and pazopanib on patients physical, social, and emotional function: result of a prospective patients reported outcome tool J Clin Oncol. 2019; 377_Suppl667–667